Abstract: An activator of PPAR&ggr; (such as pioglitazone) is useful for the treatment of a condition affecting the skin characterised by disordered fibroblast or myofibroblast function, excessive matrix production, modular fasciitis or Dupuytren's Contracture. The invention is particularly useful for treating keloids and hypertrophic scarring.

Abstract: 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine or a salt thereof is useful for the treatment of pain.

Abstract: Disclosed are compounds having formula (II): wherein: Q3, Q6a, Q6b and Q8 are independently a bond, C1-8 alkylene, C2-8 alkenylene and C2-8 alkynylene, and R3, R6a, R6b and R8 are independently hydrogen, aryl or heteroraryl, optionally substituted by halogen, hydroxy, alkoxy, nitro, cyano and carboxy, provided that: Q3R3 is not hydrogen or methyl. The compounds are effective PDE IV inhibitors and possess improved PDE IV inhibition and improved selectivity with regard to PDE III inhibition.

Abstract: Novel compounds which are effective PDE IV inhibitors are disclosed. The compounds possess improved PDE IV inhibition as compared to theophylline or rolipram, with improved selectivity with regard to, e.g., PDE III inhibition.

Abstract: Novel compounds which are effective PDE IV inhibitors are disclosed. The compounds possess improved PDE IV inhibition compared to theophylline or rolipram, with improved selectivity with regard to, e.g., PDE V inhibition. The present invention includes compounds of Formula I: wherein the substituents are as disclosed herein.

Abstract: Hypoxanthine compounds of the structure: are disclosed where R3 and R8 are as described herein. The compounds are useful as intermediates to compounds providing PDE IV inhibition activity.

Abstract: Disclosed is a compound selected from the group consisting of 1,3,8-triethyl-2,6-dithioxanthine; 1,3,8-triethyl-2-thioxanthine; 8-cyclopropyl-1-ethyl-3-(2-methyl-butyl)-6-thioxanthine; 1,3-diethyl-8-isopropyl-6-thioxanthine; 8-cyclopropyl-1,3-dipropyl-6-thioxanthine; 8-isopropyl-1,3-dipropyl-6-thioxanthine; 1,3-diethyl-8-cyclopropyl-2,6-dithioxanthine; 1-(4-chlorobenzyl)-3-ethyl-8-isopropyl-6-thioxanthine; and 8-cyclopropyl-1,3-diethyl-6-thioxanthine. Also disclosed is a pharmaceutical composition comprising at least one pharmaceutically acceptable carrier and a compound selected from the group above. Also disclosed is a method of effecting PDE IV inhibition which comprises administering to a patient suffering from a disease or disorder selected from the group consisting of asthma, allergies, PDE IV modulated inflammation, and depression, a therapeutically effective amount of a compound selected from the group above.

Abstract: Novel compounds which are effective PDE IV inhibitors are disclosed. The compounds possess improved PDE IV inhibition as compared to theophylline or rolipram, with improved selectivity with regard to, e.g., PDE V inhibition.

Abstract: The present invention relates to novel compounds of the formula (I): ##STR1## wherein Q.sub.3 R.sub.3 and Q.sub.8 R.sub.8 are described herein. The compounds possess PDE-IV inhibitory activity and improved selectivity with regard to PDE-III inhibition. Also disclosed are pharmaceutical compositions and methods of treatment utilizing the disclosed compounds.

Abstract: Disclosed are compounds of formula (I), wherein R.sup.1, R.sup.3 and R.sup.8 are independently alkyl, aryl or aralkyl, and R.sup.2 is selected from the group consisting of S and O, R.sup.6 is selected from the group consisting of S and O, provided that R.sup.2 and R.sup.6 are not both O. The compounds are effective PDE IV inhibitors and possess improved PDE IV inhibition and improved selectivity with regard to PDE III inhibition. Methods of treatment using the compounds are also disclosed.

Abstract: Disclosed is a compound of the formula (I): whereinR.sub.3, R.sub.6a and R.sub.8 are the same or different and represent a C.sub.2-8 alkyl which is unbranched or branched and unsubstituted or substituted; C.sub.3-8 cycloalkyl which is unsubstituted or substituted; C.sub.4-8 cycloalkylalkyl wherein the cycloalkyl portion is unsubstituted or substituted; aryl which is unsubstituted or substituted; aralkyl C.sub.1-4 ; heterocyclyl; and heterocyclylalkyl (C.sub.1 -C.sub.4)R.sub.6b represents H or R.sub.6a, or together R.sub.6b, N, and R.sub.6a make a C.sub.3 -C.sub.

Abstract: Disclosed is a process for the preparation of a compound of Formula IV having the structure: ##STR1## wherein R.sub.6 is N(R.sub.6a)(R.sub.6b);R.sub.3 represents a C.sub.2-8, alkyl which is unbranched or branched and unsubstituted or substituted; C.sub.3-8 cycloalkyl which is unsubstituted or substituted; C.sub.4-8 cycloalkylalkyl wherein the cycloalkyl portion is unsubstituted or substituted; aryl or benzyl which is optionally unsubstituted or substituted; ar(C.sub.1-4)alkyl; a heterocyclyl group, ring optionally substituted; heterocyclyl (C.sub.1 -C.sub.

Abstract: Novel compounds which are effective PDE IV inhibitors are disclosed. The compounds possess improved PDE IV inhibition as compared to theophylline or rolipram, with improved selectivity with regard to, e.g., PDE V inhibition. Also provided is a process of making compounds of Formula I. Compounds of the present invention are represented by Formula I: ##STR1## its pharmaceutically acceptable salts, hydrochloride salts, or prodrug forms thereof, wherein:X.sub.1a, X.sub.1b are independently selected from --NH and --N-lower alkyl;X.sub.2a, X.sub.2b are optionally present and are independently selected from S(O)n, O, CH.sub.2, and NH;P.sub.1a, P.sub.1b, P.sub.2a, P.sub.2b, P.sub.4a, and P.sub.4b are independently selected from N, or CH;R.sub.1a, R.sub.1b, R.sub.2a, R.sub.2b, R.sub.3a and R.sub.3b are independently selected from H, C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 branched alkyl, C.sub.3 -C.sub.

Abstract: Novel compounds which are effective PDE IV inhibitors are disclosed. The compounds possess improved PDE IV inhibition as compared to theophylline or rolipram, with improved selectivity with regard to, e.g., PDE III inhibition.